Samsung Wins Contract to Produce COVID-19 Treatments

Samsung Biologics has won $360 million or some 440 billion won worth of order for contract production of biopharma product from a San Francisco-based startup. Under the agreement, the South Korean company will start producing COVID-19 treatment drugs once the U.S. firm completes the development of the drugs.
Weiter zum vollständigen Artikel bei "Korea Times"